Krishna Siva Sai Kakkera, MD
Pulmonary Disease · Little Rock, ARNPI 1831445261
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,650 of the $11,243 with a category attached, or 68.0%. AstraZeneca accounts for 73.3% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $8,928, more than ten times the $146 reported in 2019.
Across 190 payments — averaging $59.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- GSK$805
- Boehringer Ingelheim$315
- Intuitive Surgical$267
- Takeda Pharmaceuticals U.S.A., Inc.$134
- Mylan Specialty L.p.$122
- plus $1K from 27 others
Across 4 payments — averaging $770.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$2K
- Boehringer Ingelheim$968
What the payments were for
- Speaking & faculty fees$7,65068%
- Food & beverage$3,57832%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $8,237 |
| GSK | 62 | $805 |
| Boehringer Ingelheim | 19 | $315 |
| Intuitive Surgical | 3 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $134 |
| Mylan Specialty L.p. | 8 | $122 |
| Merck | 5 | $109 |
| Sanofi | 4 | $107 |
| United Therapeutics Corporation | 4 | $100 |
| Insmed, Inc. | 4 | $98 |
| Regeneron Healthcare Solutions, Inc. | 4 | $88 |
| Grifols USA, LLC | 5 | $78 |
| Viatris Specialty LLC | 3 | $74 |
| Advanced Respiratory, Inc | 4 | $69 |
| Electromed, Inc. | 2 | $68 |
| Mallinckrodt Hospital Products Inc. | 3 | $63 |
| Axsome Therapeutics, Inc. | 2 | $61 |
| Philips North America LLC | 3 | $56 |
| Ambu Inc. | 2 | $49 |
| La Jolla Pharmaceutical Company | 2 | $45 |
| Pulmonx Corporation | 2 | $36 |
| Vifor Pharma, Inc. | 2 | $35 |
| Mallinckrodt Enterprises LLC | 2 | $29 |
| Ironwood Pharmaceuticals, Inc | 1 | $27 |
| AbbVie | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Baxter Healthcare | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| ERBE USA Inc | 1 | $16 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$7,775
- Da Vinci Surgical System$129
How this compares
$11,243 in reported general payments places this provider in the 80th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 142 | $92,990 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $28,981 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,647 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,545 |
| Spiriva RespimatTiotropium Bromide | 17 | $10,109 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $9,971 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,630 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $2,725 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $2,304 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,353 |
| Montelukast Sodium | 135 | $1,006 |
| Ventolin HfaAlbuterol Sulfate | 16 | $906 |
| Azelastine Hcl | 17 | $553 |
| Fluticasone Propionate | 21 | $274 |
| Doxycycline Hyclate | 15 | $138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $805 | $132,618220 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $8,237 | $20,51661 claims |
| Boehringer IngelheimSpiriva Respimat | $315 | $10,10917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Little Rock
- Nikhil MeenaLittle Rock$63K
- Hanan Khadam-MakhoulLittle Rock$15K
- Raghu ReddyLittle Rock$13K
- Eyad AbochaleLittle Rock$11K
- Samer HomsiLittle Rock$9K
- Nathan HillLittle Rock$9K
- Jose CaceresLittle Rock$6K
- Moeezullah BegLittle Rock$5K
- Rosa ArancibiaLittle Rock$4K
- Nancy RectorLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.